The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients

Clinical Neuropharmacology

Volumn 21, Issue 2, 1998, Pages 122-126

  Watanabe, Masao ^a   Iwahashi, Kazuhiko ^a   Kugoh, Toshiaki ^a   Suwaki, Hiroshi ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

CYP2C19; Genotyping; Pharmacokinetics; Phenytoin; Poor metabolizer

Indexed keywords

CARBAMAZEPINE; DNA; MEPHENYTOIN; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; EPILEPSY; ETHNIC DIFFERENCE; FEMALE; GENOTYPE; HUMAN; JAPAN; MALE; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ALLELES; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; EPILEPSY; FEMALE; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; PHENYTOIN;

EID: 0031900131     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Gonzalez FJ, Idel JR. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin Pharmacokinet 1994;26:59-70.
2. De Morais SMF, Wilkinson GR, Blaisdell J, Mayer UA, Nakamura K, Goldstein JA. Identification of new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
3. Goldstein JA, DeMorais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-99.
4. De Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Mayer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
5. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993;3:61-70.
6. Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 1982;31:301-4.
7. Grasela TH, Sheiner LB, Rainbeck B, et al. Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacokinet 1983;9:355-64.
8. Hori R, Okumura K, Kitazawa S, et al. Estimation of population parameters in Japanese patients. III. Phenytoin. Yakuzaigaku 1990;50:292-9 (in Japanese).
9. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model. J Phamacol Biopharm 1980;8:553-71.
10. Yukawa E, Higuchi S, Aoyama T. Population pharmacokinetics of phenytoin from routine clinical data in Japan. J Clin Pharm Ther 1989;24:71-7.
11. Watanabe M, Iwahashi K, Kugoh T, Suwaki H. Phenytoin kinetics in Japanese adult epileptics: phenotype of phenytoin slow metabolizers. Clin Neuropharmacol 1997;20:346-51.
12. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphism in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;46:198-207.
13. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
14. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;49:53-76.
15. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Disp 1996;24:1401-3.
16. Richens A. A study of the pharmacokinetics of phenytoin (diphenylhydantoin) in epileptic patients, and the development of a monogram for making dose increments. Epilepsia 1975;16:735-41.
17. Butler EC. The metabolic conversion of 5,5-diphenylhydantoin to 5-(p-hydroxyphenyl)-5-phenylhydantoin. J Pharmacol Exp Ther 1957;119:1-11.
18. Glazko AJ. Antiepileptic drugs: biotransformation, metabolism and serum half life. Epilepsia 1975;16:364-91.
19. Kutt H, Wolk M, Scherman R, McDowell F. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology 1964;14:542-8.
20. Vasko MR, Bell RD, Daly DD, Pippenger CE. Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther 1980;27:96-103.
21. Sloan TP, Idel JR, Smith RL. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. Clin Pharmacol Ther 1981;29:493-7.
22. De Wolff FA, Vermeij P, Ferrari MD, Buruma OJS, Breimer DD. Impairment of phenytoin parahydroxylation as a cause of severe intoxication. Ther Drug Monit 1983;5:213-5.
23. Fritz S, Lindner W, Roots I, Frey BM, Küper A. Stereochemistry of aromatic phenytoin hydroxylation in various drag hydroxylation phenotypes in humans. J Pharmacol Exp Ther 1987;241:615-22.
24. Kadar D, Fecycz TD, Kalow W. The fate of orally administered 14C-phenytoin in two healthy male volunteers. Can J Physiol Pharmacol 1983;61:403-7.
25. Veronese ME, Mackenzie PI, Doecke CJ, Mcmanus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991;175:1112-8.
26. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylation in human. Biochemistry 1994;33:1743-52.
27. Blain PG, Mucklow JC, Bacon CJ, Rawlins MD. Pharmacokinetics of phenytoin in children. Br J Pharmacol 1981;12:659-61.
28. Zielinski JJ, HaidukewYch D, Leheta BJ. Carbamazepine phenytoin interaction: elevation of plasma phenytoin concentrations due to carbamazepine comedication. Ther Drug Monit 1985;7:51-3.